What happened with BSX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Boston Scientific supplies hospitals and other health-care facilities with devices that physicians use to diagnose and treat disease, often through less-invasive procedures. Most revenue comes from single-use devices, linking sales to the procedures providers perform. The company makes most sales through its own sales organizations, while distributors and dealers serve some markets. Hospital networks and group purchasing organizations account for a substantial share of sales and can press for lower prices.
Cardiovascular devices generate most revenue. This business covers heart and blood-vessel treatments; its FARAPULSE pulsed-field ablation system accounts for most electrophysiology revenue. The other major business, MedSurg, supplies devices for digestive and urological conditions, movement disorders and chronic pain.
Demand depends on physicians choosing its devices and on government and private payers reimbursing the procedures that use them. Coverage and payment levels affect what providers buy and the prices they will pay. Commercial sales also depend on regulatory authorization: devices generally need FDA clearance or approval, unless exempt, before U.S. marketing, and must meet corresponding requirements in other countries. Those authorizations can limit permitted uses.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Boston Scientific also needs to win gastrointestinal endoscopy procedures against Olympus and Cook Medical, two important rivals missing from this list.
Medtronic challenges Boston Scientific across devices for treating atrial fibrillation, managing heart rhythm, treating blood vessels and stimulating nerves with implants; the two compete for healthcare providers' device choices.
Abbott competes with Boston Scientific for device use in heart-rhythm procedures, left atrial appendage closure, coronary intervention and nerve stimulation. Its electrophysiology and closure businesses are the relevant rivals to watch, rather than its broader healthcare sales.
Johnson & Johnson's Biosense Webster business directly challenges Boston Scientific for atrial-fibrillation ablation procedures. Watch that electrophysiology business for competitive pressure on Boston Scientific's FARAPULSE-led franchise, not Johnson & Johnson's medicine sales.
Penumbra competes with Boston Scientific in devices that remove blood clots or block vessels, but Boston Scientific has agreed to buy it with cash and shares. Watch shareholder approval, antitrust clearance and any customer disruption before closing: Penumbra's specialist-physician business is not yet part of Boston Scientific.
Merit Medical Systems competes with Boston Scientific for specialist physicians' and hospitals' purchases of peripheral vascular, cardiac and gastrointestinal endoscopy devices. Its gastrointestinal stents and related endoscopy products offer a more focused view of that rivalry than its overall cardiovascular sales.
Teleflex competes with Boston Scientific for hospitals' and healthcare providers' purchases of cardiac and peripheral intervention devices, as well as treatments for enlarged prostates. Watch its UroLift business for competition with Boston Scientific's Rezūm, rather than treating all Teleflex sales as a prostate-treatment signal.
BD competes with Boston Scientific for hospital specialists' use of vascular-intervention and urology devices. Those device lines, rather than BD's laboratory and other medical products, are the relevant competitive exposure.
Boston Scientific pays Integer Holdings Corporation to manufacture cardiovascular, heart-rhythm and nerve-stimulation devices and components, making Integer part of its supply chain. Boston Scientific accounted for more than 10% of Integer's sales in 2025, so changes in that customer business are more informative than Integer's total sales alone.
Stryker challenges Boston Scientific in devices that remove vascular blood clots and ablate nerves within vertebrae to treat chronic pain. Its Inari clot-removal products and basivertebral nerve-ablation systems are the relevant competition, not its broader orthopaedics business.
iRhythm competes with Boston Scientific's Preventice business for physician-ordered monitoring that diagnoses irregular heart rhythms outside the clinic. Watch use of its Zio patch-monitoring services, which record heart signals and return analyzed reports to physicians, for competition in this diagnostic business.
PROCEPT BioRobotics competes with Boston Scientific's prostate laser therapies and Rezūm by selling hospitals robotic systems that remove prostate tissue with a heat-free waterjet, called Aquablation. Watch uptake of its AquaBeam and HYDROS systems for competition in enlarged-prostate treatment.
AngioDynamics competes with Boston Scientific in devices clinicians use to treat peripheral blood vessels, remove clots and treat cancer through targeted procedures. Its AngioVac and AlphaVac clot-removal systems provide a concrete line to watch within that vascular rivalry.
CONMED competes with Boston Scientific for devices used in gastrointestinal endoscopy procedures. Watch its advanced endoscopic products rather than its overall general-surgery sales, which also include other surgical equipment.
Abbott Laboratories earningsABT
Abbott competes with Boston Scientific in electrophysiology and left atrial appendage closure, so its report will show how demand and competition are changing in those shared heart-device markets.
Focus on Abbott’s electrophysiology and closure businesses and any commentary on use of those procedures, not its total sales. Strong results alongside rising procedure use would support demand in markets both companies serve; Abbott growing faster than procedure use could instead point to share gains from rivals. Weak results would show less momentum at Abbott, but would not by themselves prove Boston Scientific is gaining.
Integer Holdings Corporation earningsITGR
Integer makes cardiovascular, heart-rhythm and nerve-stimulation devices and components for Boston Scientific, so its report can show whether changes in this major customer’s business are flowing through the supply chain.
If Integer reports business with Boston Scientific, focus on the change in that customer-related business rather than Integer’s total sales. An increase would be consistent with greater Boston Scientific demand for components from this supplier; a decrease could reflect weaker orders or a shift in purchasing and inventory timing. A change in Integer’s total sales alone cannot establish that Boston Scientific’s demand or supply is disrupted.
Boston Scientific Corp. earningsThis company
Boston Scientific mainly sells single-use medical devices, and this report will show whether demand for its Cardiovascular and MedSurg products is driving growth and whether costs are squeezing margins.
Compare organic sales growth in Cardiovascular and MedSurg with each segment’s reported growth and the gross margin. Organic growth excludes currency effects and specified acquisitions and divestitures. Strong Cardiovascular growth, an improving MedSurg result and a steady margin would show that demand for Boston Scientific’s own products is broadening without costs erasing the benefit of product mix. Reported growth well ahead of organic growth, or a falling margin, would point to growth relying more on currency or acquisitions, or costs squeezing profit.
CONMED Corporation earningsCNMD
CONMED’s advanced endoscopy products compete for hospital and physician purchases with Boston Scientific’s endoscopy business, so its report can show how use and competition are changing in that shared market.
Look for sales or use of CONMED’s advanced endoscopy products, not its general-surgery equipment. Growth alongside greater physician use would point to demand in the endoscopy market both companies serve; CONMED growing much faster than use could instead signal that it is winning more purchases. Weakness in those products would flag pressure in the market, but would not alone show that Boston Scientific’s endoscopy business is falling.
Teleflex Incorporated earningsTFX
Teleflex’s UroLift competes with Boston Scientific’s Rezūm for enlarged-prostate treatment, and its report can show which way hospitals’ and physicians’ choices are moving.
Watch Teleflex’s commentary on UroLift sales or use, not its overall device sales. UroLift growth would show more hospitals and physicians adopting an alternative treatment, sharpening competition for Rezūm; weakness could ease that competitive pressure but would not prove Boston Scientific sales are rising. The signal is how treatment choices are changing, not a substitute for Boston Scientific’s own results.
Penumbra, Inc. earningsPEN
Boston Scientific has agreed to buy Penumbra, but the deal has not closed; this report will show whether the specialist-physician business it plans to acquire is still growing and keeping its customers.
Focus on Penumbra’s clot-removal and vessel-treatment business and whether physicians and hospitals continue using its devices. Growth with steady customers would support the business Boston Scientific expects to add if the deal closes; slowing growth or signs of customer loss would weaken that case. The deal remains subject to closing conditions, and Penumbra is not yet part of Boston Scientific.
